Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 7, 2008, Pages 1722-1727

  Crettol, Séverine ^a   Besson, Jacques ^b   Croquette Krokar, Marina ^c   Hämmig, Robert ^d   Gothuey, Isabelle ^e   Monnat, Martine ^b   Déglon, Jean Jacques ^f   Preisig, Martin ^b   Eap, Chin B ^a  

^a Hopital de Cery   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Psychiatrische Universitatsklinik   (Switzerland)

^e Unité Ambulatoire Spécialisée   (Switzerland)

^f Fondation Phenix   (Switzerland)

Author keywords

Dopamine receptor; Genetic polymorphism; Methadone; Opioid receptor

Indexed keywords

DELTA OPIATE RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; METHADONE; MU OPIATE RECEPTOR; OPIATE RECEPTOR;

ADULT; ARTICLE; CAUCASIAN; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HEROIN DEPENDENCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECEPTORS, OPIOID;

EID: 51649125366     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.07.009     Document Type: Article

References (47)

1. Arias A., Feinn R., and Kranzler H.R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 83 (2006) 262-268
2. Barratt D.T., Coller J.K., and Somogyi A.A. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet 141B (2006) 323-331
3. Befort K., Filliol D., Décaillot F.M., Gavériaux-Ruff C., Hoehe M.R., and Kieffer B.L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276 (2001) 3130-3137
4. Bergen A.W., Kokoszka J., Peterson R., Long J.C., Virkkunen M., Linnoila M., et al. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2 (1997) 490-494
5. Berggren U., Fahlke C., Aronsson E., Karanti A., Eriksson M., Blennow K., et al. The Taqi DRD2 A1 allele is associated with alcohol-dependence although its effect size is small. Alcohol Alcohol 41 (2006) 479-485
6. Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci 245 (1995) 114-124
7. Beyer A., Koch T., Schroder H., Schulz S., and Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89 (2004) 553-560
8. Blum K., Braverman E.R., Holder J.M., Lubar J.F., Monastra V.J., Miller D., et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoact Drugs 32 (2000) 1-112 Suppl
9. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters b-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95 (1998) 9608-9613
10. Comings D.E., Gade R., Wu S., Chiu C., Dietz G., Muhleman D., et al. Studies of the potential role of the dopamine d-1 receptor gene in addictive behaviors. Mol Psychiatry 2 (1997) 44-56
11. Crettol S., Déglon J.J., Besson J., Croquette-Krokkar M., Hämmig R., Gothuey I., et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80 (2006) 668-681
12. Duan J., Wainwright M.S., Comeron J.M., Saitou N., Sanders A.R., Gelernter J., et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12 (2003) 205-216
13. Eap C.B., Buclin T., and Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41 (2002) 1153-1193
14. Elmer G.I., Pieper J.O., Rubinstein M., Low M.J., Grandy D.K., and Wise R.A. Failure of intravenous morphine to serve as an effective instrumental reinforcer in dopamine D2 receptor knock-out mice. J Neurosci 22 (2002) RC224
15. Franke P., Nothen M.M., Wang T., Neidt H., Knapp M., Lichtermann D., et al. Human delta-opioid receptor gene and susceptibility to heroin and alcohol dependence. Am J Med Genet 88B (1999) 462-464
16. Hirvonen M., Laakso A., Nagren K., Rinne J.O., Pohjalainen T., Hia J., et al. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 9 (2004) 1060-1061
17. Höllt V. A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 12 (2002) 1-2
18. Kim D.J., Park B.L., Yoon S., Lee H.K., Joe K.H., Cheon Y.H., et al. 5′ UTR polymorphism of dopamine receptor D1 (DRD1) associated with severity and temperament of alcoholism. Biochem Biophys Res Commun 357 (2007) 1135-1141
19. Klepstad P., Rakvag T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., et al. The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48 (2004) 1232-1239
20. Kreek M.J., Bart G., Lilly C., LaForge K.S., and Nielsen D.A. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57 (2005) 1-26
21. Lawford B.R., Young R.M., Noble E.P., Sargent J., Rowell J., Shadforth S., et al. The D2 dopamine receptor A1 allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 96B (2000) 592-598
22. Li T., Liu X., Zhao J., Hu X., Ball D.M., Loh E., et al. Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects. Am J Med Genet 114B (2002) 329-335
23. Limosin F., Loze J.Y., Rouillon F., Ades J., and Gorwood P. Association between dopamine receptor D1 gene DdeI polymorphism and sensation seeking in alcohol-dependent men. Alcohol Clin Exp Res 27 (2003) 1226-1228
24. Lötsch J., and Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy?. Trends Mol Med 11 (2005) 82-89
25. Lötsch J., Skarke C., Grosch S., Darimont J., Schmidt H., and Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12 (2002) 3-9
26. Lötsch J., Skarke C., Wieting J., Oertel B.G., Schmidt H., Brockmöller, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 79 (2006) 72-89
27. Maldonado R., Saiardi A., Valverde O., Samad T.A., Roques B.P., and Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 388 (1997) 586-589
28. Mayer P., and Hollt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 16 (2006) 1-7
29. Mayer P., Rochlitz H., Rauch E., Rommelspacher H., Hasse H.E., Schmidt A., et al. Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport 8 (1997) 2547-2550
30. Neville M.J., Johnstone E.C., and Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23 (2004) 540-545
31. Noble E.P. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet 116B (2003) 103-125
32. Nurnberger Jr. J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51 (1994) 849-859
33. Oertel B.G., Schmidt R., Schneider A., Geisslinger G., and Lötsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 16 (2006) 625-636
34. Persico A.M., Bird G., and Gabbay FH Uhl G.R. D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry 40 (1996) 776-784
35. Romberg R.R., Olofsen E., Bijl H., Taschner P.E., Teppema L.J., Sarton E.Y., et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102 (2005) 522-530
36. Rommelspacher H., Smolka M., Schmidt L.G., Samochowiec J., and Hoehe M.R. Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol 24 (2001) 129-135
37. Sander T., Ladehoff M., Samochowiec J., Finckh U., Rommelspacher H., and Schmidt L.G. Lack of an allelic association between polymorphisms of the dopamine D2 receptor gene and alcohol dependence in the German population. Alcohol Clin Exp Res 23 (1999) 578-581
38. Shahmoradgoli N.M., Ohadi M., Joghataie M.T., Valaie F., Riazalhosseini Y., Mostafavi H., et al. Association between the DRD2 A1 allele and opium addiction in the Iranian population. Am J Med Genet 134B (2005) 39-41
39. Smolka M., Sander T., Schmidt L.G., Samochowiec J., Rommelspacher H., Gscheidel N., et al. Mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psychoneuroendocrinology 24 (1999) 629-638
40. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gatley S.J., Gifford A., et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 156 (1999) 1440-1443
41. Volkow N.D., Wang G.J., Fowler J.S., Thanos P.P., Logan J., Gatley S.J., et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 46 (2002) 79-82
42. Wong A.H.C., Buckle C.E., and Van Tol H.H.M. Polymorphisms in dopamine receptors: what do they tell us?. Eur J Pharmacol 410 (2000) 183-203
43. World Health Organization G: Diagnosis and clinical measurement in Psychiatry. In: Wing J.K., Sartorious N., and Ustun T.B. (Eds). A reference model for Schedules for assessment in Neuropsychiatry (SCAN) (1992), Geneva, Switzerland
44. Xu K., Liu X.H., Nagarajan S., Gu X.Y., and Goldman D. Relationship of the delta-opioid receptor gene to heroin abuse in a large Chinese case/control sample. Am J Med Genet 110 (2002) 45-50
45. Xu K., Lichtermann D., Lipsky R.H., Franke P., Liu X., Hu Y., et al. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry 61 (2004) 597-606
46. Young R.M., Lawford B.R., Nutting A., and Noble E.P. Advances in molecular genetics and the prevention and treatment of substance misuse: implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addict Behav 29 (2004) 1275-1294
47. Zhang Y., Wang D., Johnson A.D., Papp A.C., and Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280 (2005) 32618-32624